Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-371-8300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.36 million
Profitability
Miscellaneous
Employees36
OptionableNot Optionable
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
What is Jaguar Health's stock symbol?
Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."
How were Jaguar Health's earnings last quarter?
Jaguar Health Inc (NASDAQ:JAGX) announced its earnings results on Monday, November, 19th. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $1.13 million for the quarter. Jaguar Health had a negative return on equity of 259.67% and a negative net margin of 908.28%. View Jaguar Health's Earnings History.
When is Jaguar Health's next earnings date?
Has Jaguar Health been receiving favorable news coverage?
Press coverage about JAGX stock has trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Jaguar Health earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Are investors shorting Jaguar Health?
Jaguar Health saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 158,314 shares, a decline of 70.7% from the December 14th total of 539,754 shares. Based on an average daily volume of 521,907 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the company's stock are short sold. View Jaguar Health's Current Options Chain.
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include Aridis Pharmaceuticals (ARDS), Avenue Therapeutics (ATXI), Immune Design (IMDZ), Merrimack Pharmaceuticals (MACK), Neos Therapeutics (NEOS), BIOLINERX LTD/S (BLRX), Otonomy (OTIC), Sienna Biopharmaceuticals (SNNA), Achaogen (AKAO), IMMUTEP LTD/S (IMMP), Sesen Bio (SESN), Oramed Pharmaceuticals (ORMP), AEterna Zentaris (AEZS), Synergy Pharmaceuticals (SGYP) and Innovate Biopharmaceuticals (INNT).
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the folowing people:
- Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 60)
- Ms. Karen S. Wright, CFO & Treasurer (Age 63)
- Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 61)
- Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 56)
- Mr. Jonathan S. Wolin, Chief Compliance Officer & Corp. Counsel
When did Jaguar Health IPO?
(JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
How do I buy shares of Jaguar Health?
Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jaguar Health's stock price today?
One share of JAGX stock can currently be purchased for approximately $0.26.
How big of a company is Jaguar Health?
Jaguar Health has a market capitalization of $17.33 million and generates $4.36 million in revenue each year. Jaguar Health employs 36 workers across the globe.
What is Jaguar Health's official website?
How can I contact Jaguar Health?
Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.
MarketBeat Community Rating for Jaguar Health (NASDAQ JAGX)
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
